Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study

Overview of attention for article published in Gastroenterology, March 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 10 news outlets
twitter: 11 X users
patent: 3 patents
facebook: 1 Facebook page

guideline: 2 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 11 news stories from 10 outlets.

Guselkumab and Intestinal Stenosis in Crohn’s Disease, With David Rubin, MD

Consultant Live, 19 Oct 2026

Patients with moderately to severely active Crohn’s disease (CD) and non-passable intestinal stenosis at baseline had…

Phase-3-Studie GRAVITI: Guselkumab bei aktivem Morbus Crohn

DeutschesGesundheitsPortal, 08 Jun 2026

Das GesundheitsPortal für innovative Arzneimittel, neue Therapien und neue Heilungschancen Original Titel: Efficacy and Safety…

Phase-3-Studie GRAVITI: Guselkumab bei aktivem Morbus Crohn

MedWiss, 08 Jun 2026

Original Titel: Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to…

Guselkumab demuestra eficacia sostenida en enfermedad de Crohn activa de moderada a grave

El Medico Interactivo, 28 Jul 2025

Un nuevo biológico emerge con solidez en la terapéutica del Crohn moderado a grave El estudio GRAVITI de fase 3, publicado en…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.